Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

Sponsor

Guangdong Raynovent Biotech Co., Ltd (Industry)

Overall Status

Completed

CT.gov ID

NCT04024137

Collaborator

(none)

172

Enrollment

Locations

Arms

5.4

Actual Duration (Months)

6.6

Patients Per Site

1.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the antiviral effect, as measured by the time to alleviation of influenza symptoms and viral titer in nasopharyngeal secretions in adults with acute uncomplicated influenza A following administration of ZSP1273.

Condition or Disease	Intervention/Treatment	Phase
Influenza A	Drug: ZSP1273 200 mg Drug: Placebo Drug: ZSP1273-400 mg Drug: Placebo Drug: ZSP1273-600 mg Drug: Placebo Drug: Placebo	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

172 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study of ZSP1273 in Adults With Acute Uncomplicated Influenza A

Actual Study Start Date :

Dec 7, 2019

Actual Primary Completion Date :

May 18, 2020

Actual Study Completion Date :

May 18, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: ZSP1273-200 mg BID Subjects will receive 10 doses of ZSP1273 200mg along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.	Drug: ZSP1273 200 mg 1 X 200-mg tablet taken orally Drug: Placebo 2 tablets taken orally
Experimental: ZSP1273-400 mg BID Subjects will receive 10 doses of ZSP1273 400mg（200mg*2) along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.	Drug: ZSP1273-400 mg 2 X 200-mg tablet taken orally Drug: Placebo 1 tablet taken orally
Experimental: ZSP1273-600 mg QD Subjects will receive 5 doses of ZSP1273 600mg （200mg *3) and 5 doses of placebo respectively for 5 days.The interval between ZSP1273 and placebo is approximately 12 hour (+/- 2) .	Drug: ZSP1273-600 mg 3 X 200-mg tablet taken orally Drug: Placebo 3 tablets taken orally
Placebo Comparator: Placebo Subjects will receive 10 doses of matching placebo of ZSP1273 twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.	Drug: Placebo Subjects will receive matching placebo of ZSP1273

Outcome Measures

Primary Outcome Measures

Time to alleviation of influenza symptoms in participants [Initiation of study treatment (Day 1) up to Day 15]
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all 7 influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours

Secondary Outcome Measures

AUC of the log10 pharyngeal viral load [Days 6]
Area under the curve (AUC) of the log10 pharyngeal viral load is measured by viral culture and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).
Change in the total score of 7 influenza symptoms [Up to Day15]
Participants assessed the severity of seven influenza-associated symptoms(cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms(Sum of symptom scores) as assessed by the participant, and ranges from 0 to 21.
Time to alleviation of each influenza symptom. [Up to Day15]
Participants assessed the severity of seven influenza-associated symptoms(cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time to Resolution of Fever [Up to Day15]
Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours.
Proportion of patients reporting normal temperature [Up to Day15]
Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.
Percentage of subjects with virus titer detected [Days 2,4, 6]
Influenza virus RNA was quantified from throat swabs.Proportion of patients positive for influenza virus titer is defined as the percentage of patients whose virus titer is not less than the lower limit of quantification among those assessed for virus titer measured by viral culture and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) on Days 2,4, 6.
Duration of detectable virus [Days 2,4, 6]
Defined as the time from the start of treatment to the time when the titer is less than the lower limit of quantification measured by viral culture and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).
Change in virus titer [Days 2,4, 6]
Defined as the change from baseline in virus titer measured by viral culture and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).
Change in viral RNA load [Days 2,4, 6]
Defined as the change from baseline in viral RNA load measured by viral culture and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) on Days 2, 4, 6.
Incidence of influenza-related complications [Up to Day21]
Defined as the percentage of subjects in the analysis population who experience each influenza-related complication (sinusitis, otitis media, bronchitis, and pneumonia) as an adverse event after the initiation of the study treatment.
Time to return to normal activities of daily life [Up to Day15]
Participants were asked to record their activities of daily life on a scale from 0 (worst possible health) to 10 (normal activities of daily life). Time to return to normal activities of daily life defined as the time between the initiation of the study treatment and the return to normal activities of daily life. The return to normal activities of daily life is defined as the time when the subject assesses his/her activities as 10.Subjects with a baseline self-rated daily activity score of 10 are not included in this analysis.
Proportion of patients with the Serological conversion of neutralizing antibody titer relative to that in Visit 1 ≥4 [Baseline and Day 21]
Defined as the protprtion of patients with a ratio of 4 or more at Visit 5 antibody titer relative to Visit 1 titer
Proportion of patients and frequency in combination use of acetaminophen. [Up to 21 days post-dose]
The proportion of patients who use acetaminophen in the duration of the study
Change in EQ-5D-5L [Baseline up to Day 15]
Defined as the change from baseline in the index value and that in EQ VAS score as calculated from the EQ-5D-5L questionnaire.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Males and female subjects between 18-65 years (Both inclusive).
Patients with a diagnosis of influenza virus A infection confirmed by all of the following:

Positive Rapid Antigen Test (RAT) with throat swabs;and
Fever≥38.0ºC (axillary) in the predose examinations;and
At least one of the following general systemic symptoms and respiratory symptoms respectively associated with influenza are present with a severity of moderate or greater:
General systemic symptoms:Headache,Feverishness or chills,Muscle or joint pain,Fatigue;
Respiratory symptoms:Cough,Sore throat,Nasal congestion.

The time interval between the onset of symptoms and the enrollment is≤48 hours. The onset of symptoms is defined as:

Time of the first increase in body temperature(axillary temperature≥38.0ºC),or
Time when the patient experiences at least one general or respiratory symptom.

Subjects who agree to use an appropriate method of contraception during the study and up to 6 months after drug withdrawal.
Signature of a dated Informed Consent Form (ICF) indicating that the subject has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.

Exclusion Criteria:

Known hypersensitivity and/or allergy to some drugs and food,especially for the composition that is similar to ZSP1273;
Dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs.
Use of the following medications within 7 days prior to screening:

Influenza antiviral medication:oseltamivir,peramivir,famivir,abidol,amantadine or rimantadine.
Chinese patent medicine or herbal medicine with antiviral effect.

Patients who have received influenza vaccine within 6 months prior to enrollment.
Presence of clinically significant abnormalities in ECG .
Chest X - ray examination confirmed bronchitis,pneumonia,pleural effusion or pulmonary interstitial lesions.
Patients who have experienced respiratory tract infection,Otitis media,nasosinusitis.
White blood cells(WBC)>10.0×109/L at screening.
Subject who produces purulent sputum or has suppurative tonsillitis.
Patients with severe or uncontrollable underlying diseases:blood disorders,severe chronic obstructive pulmonary disease(COPD),liver disorders(ALT or AST≥3 ULN,total bilirubin≥1.5 ULN),kidney disorders(serum creatinine>177μmol/L or 2mg/dL),chronic congestive heart failure(NYHA III-IV),mental disorders.
Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus [HIV] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment.
Concomitant therapy with aspirin or salicylic acid.
Morbid obesity(Body mass index [BMI]≥30kg/m2).
Known history of alcohol abuse or drug abuse.
Pregnancy or breastfeeding at screening and during the study.All female subjects of childbearing potential must have a negative urine pregnancy test at screening and during the trial.
Have received any other investigational products within 3 months prior to dosing.
Subjects who should not be included in the study in the opinion of the Investigator.

Contacts and Locations

Locations

	Site	City	State	Country
1	The Second Hospital Of Anhui Medical University	Hefei	Anhui	China
2	Beijing Ditan Hospital Capital Medical University	Beijing	Beijing	China
3	Beijing Luhe Hospital,Capital Medical University	Beijing	Beijing	China
4	Peking University Third Hospital	Beijing	Beijing	China
5	Zhongshan Hospital Xiamen University	Xiamen	Fujian	China
6	Dongguan people's Hospital	Dongguan	Guangdong	China
7	Nanfang Hospital,South Medical Hospital	Guangzhou	Guangdong	China
8	The First Affiliated Hospital Of Guangzhou Medical University	Guangzhou	Guangdong	China
9	Traditional Chinese Medicine Hospital of Guangdong Province	Guangzhou	Guangdong	China
10	Huizhou Municipal Central Hospital	Huizhou	Guangdong	China
11	Jieyang People's Hospital	Jieyang	Guangdong	China
12	Shenzhen People's Hospital	Shenzhen	Guangdong	China
13	Affiliated Hospital Of Guangdong Medical University	Zhanjiang	Guangdong	China
14	Henan Provincial People's Hospital	Zhengzhou	Henan	China
15	The Sixth People's Hospital Of Zhengzhou	Zhengzhou	Henan	China
16	Sir Run Run Hospital Nanjing Medical University	Nanjing	Jiangsu	China
17	Jiujiang University Hospital	Jiujiang	Jiangxi	China
18	The First Affiliated Hospital Of Nanchang University	Nanchang	Jiangxi	China
19	Shengjing Hospital of China Medical University	Shenyang	Liaoning	China
20	Linyi People's Hospital	Linyi	Shandong	China
21	Qingdao Municipal Hospital	Qingdao	Shandong	China
22	First Hospital of Shanxi Medical University	Taiyuan	Shanxi	China
23	Chengdu Fifth People's Hospital	Chengdu	Sichuan	China
24	General Hospital, Tianjin Medical University	Tianjin	Tianjin	China
25	The First Affiliated Hospital,Zhejiang University	Hangzhou	Zhejiang	China
26	Zhejiang Provincial People's Hospital	Hangzhou	Zhejiang	China

Sponsors and Collaborators

Guangdong Raynovent Biotech Co., Ltd

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Guangdong Raynovent Biotech Co., Ltd

ClinicalTrials.gov Identifier:

NCT04024137

Other Study ID Numbers:

ZSP1273-18-02

First Posted:

Jul 18, 2019

Last Update Posted:

Jun 4, 2020

Last Verified:

Dec 1, 2019

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Influenza, Human

Study Results

No Results Posted as of Jun 4, 2020